2025-12-19 19:30:00

Three major pharmaceutical companies out of seventeen are expected to finalize negotiations next week, according to recent policy updates. The remaining firms have yet to align with the proposed framework, signaling ongoing discussions in the sector. This development highlights the ongoing tension between regulatory expectations and corporate compliance in the pharmaceutical industry. Investors are closely monitoring how these negotiations conclude, as policy shifts can significantly impact market dynamics and industry-wide standards.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

19 Likes

Reward
19
6
Repost
Share

Comment

0/400

ser_we_are_early

· 2025-12-19 23:55

Oh dear, it's the same old tired "three birds out in front" act again, while the remaining fourteen are still dawdling.

View OriginalReply0

tokenomics_truther

· 2025-12-19 19:50

In this round of policy negotiations in the pharmaceutical industry, only three out of seventeen companies will get it done next week? To put it simply, the big players are getting priority clearance, while the smaller ones are still arguing among themselves.

View OriginalReply0

mev_me_maybe

· 2025-12-19 19:48

It's the same policy tug-of-war again. Out of 17 companies, only 3 have been settled? The rest are still dragging their feet. This pace is really slow.

View OriginalReply0

FUD_Whisperer

· 2025-12-19 19:42

Here we go again, the pharmaceutical companies are bickering again? Out of 17, only 3 have sorted it out, the others are still dragging their feet... This is the cost of compliance.

View OriginalReply0

GasFeeNightmare

· 2025-12-19 19:41

Is this another regulatory tug-of-war? Do pharmaceutical companies really not understand?

View OriginalReply0

MevShadowranger

· 2025-12-19 19:31

Oh no, it's the same old regulation and oversight. Are the pharmaceutical companies still dithering? Only three have been dealt with, while the remaining fourteen are just slacking off.

View OriginalReply0